Geovax announces $10 million private placement

Atlanta, ga, jan. 14, 2022 (globe newswire) -- via  newmediawire -- geovax labs, inc. (nasdaq: govx), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single institutional investor to raise approximately $10.0 million through the private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with an accompanying warrant at a combined effective purchase price of $3.26. the warrants will be exercisable immediately at an exercise price of $3.26 per share and will expire five years from the date of issuance. the closing of the private placement is expected to occur on january 19, 2022, subject to the satisfaction of certain customary closing conditions set forth in the securities purchase agreement.
GOVX Ratings Summary
GOVX Quant Ranking